Connected Work
We are in an increasingly volatile global climate, from health and economic crises, to trade wars on multiple fronts, to political unease, to name just a few.
Strategy
Proactively Shaping the Transformation Path
The goal of a CO2-neutral chemical industry in 2050 is comparable with a 30 year marathon – but at sprint speed. So we have to find the best route to this common goal. This is the conclusion of a conference organized by the Association for Chemistry and Economics (VCW), a sub-sector of the German Chemical Society (GDCh).
Trade, Innovation and Investment
US chemistry remains in demand around the world despite ongoing trade tensions and Covid-19. In 2019, the US chemical industry was one of the world’s largest exporters, at $136 billion. The industry has a large and growing trade surplus, reaching more than $35 billion in 2019.
Chemical Industry on the Edge of a Disruptive Digital Revolution
While the focus of digitization in Europe and North America is on process efficiency and costs, the focus in Asia-Pacific is on market and customer access.
Changes in Trade with the United Kingdom
On Dec. 31, 2020, the UK will leave the EU single market and customs union. Regardless of any agreement reached with the EU, the end of the Brexit transition period will affect citizens, businesses, as well as travel between the UK and EU. Therefore, businesses need to prepare themselves for the upcoming changes.
Foreign Investment in China`s Chemical Industry
Investment in the areas listed in the catalogue is supported by a variety of incentives.
The Coronavirus Crisis: Challenges and Opportunities for CMOs, CDMOs and CROs
The coronavirus crisis caused by the Covid-19 pandemic has uncovered problems that have been smoldering beneath the surface of the pharmaceutical industry — including CMOs/CDMOs and CROs — and need to be addressed. That supply chains are vulnerable to disruption when major development, production and transportation hubs are blocked or shut down has become painfully obvious.
Expert Interview: Andrew Henderson, Sterling Pharma Solutions
So far, the pharmaceutical industry — including CMOs/CDMOs and CROs — has responded well to the outbreak of the Covid-19 pandemic. However, the coronavirus crisis has uncovered problems that have been smoldering beneath the surface and need to be addressed. That supply chains are vulnerable to disruption when major development, production and transportation hubs are blocked or shut down has become painfully obvious.
Expert Interview: Mark Quick, Recipharm
So far, the pharmaceutical industry — including CMOs/CDMOs and CROs — has responded well to the outbreak of the Covid-19 pandemic. However, the coronavirus crisis has uncovered problems that have been smoldering beneath the surface and need to be addressed. That supply chains are vulnerable to disruption when major development, production and transportation hubs are blocked or shut down has become painfully obvious.
Expert Interview: Peter Halkjaer-Knudsen, Raybow Pharmaceuticals
So far, the pharmaceutical industry — including CMOs/CDMOs and CROs — has responded well to the outbreak of the Covid-19 pandemic. However, the coronavirus crisis has uncovered problems that have been smoldering beneath the surface and need to be addressed. That supply chains are vulnerable to disruption when major development, production and transportation hubs are blocked or shut down has become painfully obvious.
Expert Interview: Matthew Moorcroft, Lonza
So far, the pharmaceutical industry — including CMOs/CDMOs and CROs — has responded well to the outbreak of the Covid-19 pandemic. However, the coronavirus crisis has uncovered problems that have been smoldering beneath the surface and need to be addressed. That supply chains are vulnerable to disruption when major development, production and transportation hubs are blocked or shut down has become painfully obvious.
Expert Interview: Alan Walker, Kaneka
So far, the pharmaceutical industry — including CMOs/CDMOs and CROs — has responded well to the outbreak of the Covid-19 pandemic. However, the coronavirus crisis has uncovered problems that have been smoldering beneath the surface and need to be addressed. That supply chains are vulnerable to disruption when major development, production and transportation hubs are blocked or shut down has become painfully obvious.
Expert Interview: David Zimmermann, Kalexsyn
So far, the pharmaceutical industry — including CMOs/CDMOs and CROs — has responded well to the outbreak of the Covid-19 pandemic. However, the coronavirus crisis has uncovered problems that have been smoldering beneath the surface and need to be addressed. That supply chains are vulnerable to disruption when major development, production and transportation hubs are blocked or shut down has become painfully obvious.
Expert Interview: Andrew Thompson, J-Star
So far, the pharmaceutical industry — including CMOs/CDMOs and CROs — has responded well to the outbreak of the Covid-19 pandemic. However, the coronavirus crisis has uncovered problems that have been smoldering beneath the surface and need to be addressed. That supply chains are vulnerable to disruption when major development, production and transportation hubs are blocked or shut down has become painfully obvious.
Expert Interview: Jean-Luc Herbeaux, Hovione
So far, the pharmaceutical industry — including CMOs/CDMOs and CROs — has responded well to the outbreak of the Covid-19 pandemic. However, the coronavirus crisis has uncovered problems that have been smoldering beneath the surface and need to be addressed. That supply chains are vulnerable to disruption when major development, production and transportation hubs are blocked or shut down has become painfully obvious.
Expert Interview: GianMarco Negrisoli, Flamma
So far, the pharmaceutical industry — including CMOs/CDMOs and CROs — has responded well to the outbreak of the Covid-19 pandemic. However, the coronavirus crisis has uncovered problems that have been smoldering beneath the surface and need to be addressed. That supply chains are vulnerable to disruption when major development, production and transportation hubs are blocked or shut down has become painfully obvious.
Expert Interview: Peter Pekos, Dalton Pharma Services
So far, the pharmaceutical industry — including CMOs/CDMOs and CROs — has responded well to the outbreak of the Covid-19 pandemic. However, the coronavirus crisis has uncovered problems that have been smoldering beneath the surface and need to be addressed. That supply chains are vulnerable to disruption when major development, production and transportation hubs are blocked or shut down has become painfully obvious.
Expert Interview: Michael Quirmbach, CordenPharma
So far, the pharmaceutical industry — including CMOs/CDMOs and CROs — has responded well to the outbreak of the Covid-19 pandemic. However, the coronavirus crisis has uncovered problems that have been smoldering beneath the surface and need to be addressed. That supply chains are vulnerable to disruption when major development, production and transportation hubs are blocked or shut down has become painfully obvious.
Into the Crucible: Will the European Chemicals Industry Rise to the Circularity Challenge?
Chemicals are a critical, but often overlooked, factor of success for a circular economy. 96% of all products on European markets, from food to medical treatments, from buildings to consumer electronics, rely on chemicals, so this shouldn’t come as a surprise. But what does circularity mean for the future of the chemicals industry? Should it embrace circular systems or resist them?
The Importance of Innovation for Future Success
Innovative strength has been a cornerstone of Bachem’s business success since the founding nearly 50 years ago. Günther Loidl, Chief Technology Officer for Bachem Holding, talks about a new innovation management system that will further heighten the importance of innovation in the future.
Facing Strong Headwinds
So far, the pharmaceutical industry — including CMOs/CDMOs — has responded well to the outbreak of the Covid-19 pandemic.
Expansions in High-Potency API Manufacturing
DCAT Value Chain Insights rounds up recent expansion activity for highly potent drug substances and drug products.
Continuation Rather than a Change
China`s 14th Five-Year Plan (FYP) covering the period from 2021 to 2025 will only be published after its acceptance by the National People`s Congress in March 2021.
Evolving an Entrepreneurial Ecosystem
We are in the midst of a start-up revolution. The growth of innovation-driven start-up activity is profound and global in scope, and it is a driving force of change even in mature industries such as the chemical and pharmaceutical sector.
Hydrogen – a Market with Potential
Linde intends to further expand its hydrogen business by investing in electrolysis capacities and infrastructure.
Will BASF Turn to Pig Farming? Not quite, but …
Why BASF Venture Capital is investing in SmartAHC, a supplier of digitalization solutions for pig farming on the Chinese market.
Line Products as a Growth Market
The WeylChem Group of companies consists of seven operating and two R&D sites in Europe and the USA as well as the global sales and marketing platform, WeylChem International.
Circular Economy
The chemical industry is on the threshold of a new era – the age of circularity. We asked industry experts to share their opinions on this transformational topic.
Predictive Fluid Modelling
Virtual Prototyping of Complex Fluids and Flowing Materials
Transition to Circular Economy: No Time to Stand Still
The shift to a circular economy requires intensive cooperation along the chemical value chain and across industries.
Consolidation, Risk Reduction and Demand Shift
Like most industries, the global chemical industry is currently strongly affected by the outbreak of Covid-19.
